Xenetic Biosciences
XBIO
14 hedge funds and large institutions have $1.07M invested in Xenetic Biosciences in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.31% less ownership
Funds ownership: 1.09% → 0.78% (-0.31%)
36% less funds holding
Funds holding: 22 → 14 (-8)
43% less capital invested
Capital invested by funds: $1.88M → $1.07M (-$814K)
97% less call options, than puts
Call options by funds: $2K | Put options by funds: $61K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$10.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.86K |
| 3 |
State Street
Boston,
Massachusetts
|
+$803 |
| 4 |
Morgan Stanley
New York
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$164K |
| 2 |
Renaissance Technologies
New York
|
-$72.8K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$63K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$60.5K |
| 5 |
VF
Virtu Financial
New York
|
-$59K |
XBIO Hedge Fund Activity: Q1 2022 in Review
14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2022, worth a combined $1.07M — down 43% from $1.88M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of XBIO and 0 opened new positions — a net loss of 8 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was JP Morgan Private Wealth Advisors, adding an estimated $10.4K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $164K sold.
- 14 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2022, down from 22 in Q4 2021.
- Funds reported $1.07M of Xenetic Biosciences stock for Q1 2022, down 43% quarter-over-quarter.
- 0 funds opened new Xenetic Biosciences positions in Q1 2022 and 8 closed out, a net change of -8 holders.
- The largest Xenetic Biosciences buyer in Q1 2022 was JP Morgan Private Wealth Advisors, an estimated $10.4K added.
- The largest Xenetic Biosciences seller in Q1 2022 was Susquehanna International Group, an estimated $164K sold.
Based on aggregated 13F filings for Q1 2022.